Back to results
US 2014/0155322 A1Published application
Method of Preventing Or Reducing Scarring Of Human Skin
AssigneePharmecosse Ltd.
InventorsClaire Linge, Ian Paul Mackie
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneePharmecosse Ltd.
InventorsClaire Linge, Ian Paul Mackie
Estimating the term…
Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring.
A method of reducing dermal scarring in a skin wound of a human, which comprises administering to the skin wound, in a period consisting of up to about 2 days after the wound is formed and before a peak myofibroblast level is reached in the wound, an effective amount of an active agent selected from insulin and a specific peroxisome proliferator-activated receptor gamma (PPARγ) agonist.
A method of reducing dermal scarring in the healed skin of a human after formation of a wound while maintaining a breaking strength of the healed skin substantially corresponding to that of healed skin which includes natural levels of scar tissue, which method comprises administering to the skin, in a period consisting of up to about 2 days after the wound is formed and before a peak myofibroblast level is reached in the wound, an effective amount of an active agent selected from insulin and a specific peroxisome proliferator-activated receptor gamma (PPARγ) agonist.
Dependencies are inferred from the claim text.